Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email in the first instance.

 Information  X 
Enter a valid email address

Antisoma plc (SRC)

  Print      Mail a friend       Annual reports

Friday 15 August, 2008

Antisoma plc

Evidence of activity seen in new data from ASA4...

London, UK, and Cambridge, MA, 15 August 2008 - Antisoma plc
(LSE:ASM; USOTC: ATSMY) today announced survival data from its phase
II study of ASA404 in hormone-refractory prostate cancer, in which
patients were randomised to receive either 1200 mg/m2 ASA404 plus the
chemotherapy drug docetaxel or a control treatment of docetaxel

The hazard ratio expressing the relative risk of death in the ASA404
and control groups favoured the ASA404 group (hazard ratio 0.8; 95%
confidence intervals 0.46-1.39). Median survival in the two groups
was similar at 17.0 and 17.2 months, respectively, while two-year
survival was 33% with ASA404 and 23% in the control group.

Previously reported findings from the same trial have shown higher
tumour response rates and markedly higher PSA response rates in
patients receiving ASA404.

Antisoma's partner Novartis is considering what the next steps should
be in prostate cancer as part of a wider analysis of potential
indications for development. A phase III development programme is
already ongoing in lung cancer, and plans for development in other
indications are being considered.

Glyn Edwards, Antisoma's CEO, said: "Following the very positive
phase II data in lung cancer, it does not surprise us to see further
evidence of ASA404's activity in prostate cancer. With its unique
mode of action as a tumour-vascular disrupting agent, ASA404 has
potential against a variety of solid tumours."

A webcast and conference call will be held today at 2pm BST/ 9am EDT.
The webcast can be accessed via Antisoma's website at and the call by dialling +44 (0)20 8609 1435
(UK toll-free 0808 109 1498; US toll-free 1866 793 4279) and using
the participant PIN code 965983#. A recording will also be available
afterwards on the Antisoma website.


Glyn Edwards, CEO
Daniel Elger, Director of Communications
Antisoma plc                                      +44 (0)7909 915 068

Mark Court/Lisa Baderoon/Rebecca Skye Dietrich

Buchanan Communications                           +44 (0)20 7466 5000

Brian Korb
The Trout Group                                   +1 646 378 2923

About ASA404
ASA404 (DMXAA) is a small-molecule Tumour-Vascular Disrupting Agent
(Tumour-VDA) which targets the blood vessels that nourish tumours.
The drug was discovered by Professors Bruce Baguley and William Denny
and their teams at the Auckland Cancer Society Research Centre,
University of Auckland, New Zealand. It was in-licensed by Antisoma
from Cancer Research Ventures Limited (now Cancer Research
Technology), the development and commercialisation company of the
Cancer Research Campaign (now Cancer Research UK), in August 2001.
Worldwide rights to the drug were licensed to Novartis AG in April
2007. ASA404 is currently being tested in a phase III pivotal study
in the first-line treatment of non-small cell lung cancer (NSCLC),
and will enter a second phase III pivotal study in the second-line
treatment of NSCLC later this year. ASA404 may have potential against
a number of solid tumours and is regarded as having the potential to
achieve blockbuster sales.

About the ASA404 trial in prostate cancer
Patients enrolled in the ASA404 prostate cancer phase II trial had
metastatic hormone-refractory prostate cancer. Seventy-four patients
were randomised to receive either docetaxel alone or docetaxel plus
ASA404. Endpoints in the study included PSA response rate (the
proportion of patients who showed a sustained 50% decline in the
level of prostate-specific antigen (PSA)), RECIST response rates
(proportion of patients who showed tumour reductions according to the
'Response Evaluation Criteria in Solid Tumours'), time to tumour
progression (TTP; the time before disease recurrence was apparent)
and median survival. Data on PSA response, RECIST response and TTP
have been reported previously, and were as follows in the ASA404 and
control groups, respectively: PSA response 59 vs 37%; RECIST response
23 vs 9%; TTP 7.3 vs 6.9 months. Survival findings are detailed

About Antisoma
Antisoma is a London Stock Exchange-listed biopharmaceutical company
that develops novel products for the treatment of cancer. The Company
has operations in the UK and the US. Please visit
for further information about Antisoma.

Except for the historical information presented, certain matters
discussed in this statement are forward looking statements that are
subject to a number of risks and uncertainties that could cause
actual results to differ materially from results, performance or
achievements expressed or implied by such statements. These risks and
uncertainties may be associated with product discovery and
development, including statements regarding the company's clinical
development programmes, the expected timing of clinical trials and
regulatory filings. Such statements are based on management's current
expectations, but actual results may differ materially.